Journal of Bone and Mineral Metabolism

, Volume 27, Issue 1, pp 110–113 | Cite as

Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis

Short Communication

Abstract

Langerhans cell histiocytosis (LCH) is a rare disease, probably an atypical myeloproliferative syndrome, with variable clinical presentation and behavior. In this report, we focus on bone involvement by LCH and treatment with zoledronic acid in six patients as they progressed after chemotherapy and radiotherapy. Zoledronic acid appeared safe and produced significant relief in pain.

Keywords

Langerhans cell histiocytosis Bone lesions Zoledronic acid 

References

  1. 1.
    Arceci RJ (2002) Langerhans cell histiocytosis in children and adults: pathogenesis, clinical manifestations, and treatment. Hematology (Am Soc Hematol Educ Program) 1:297–304Google Scholar
  2. 2.
    Histiocytosis Association of America. http://www.histio.org. Cited July 2007
  3. 3.
    Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, Komp D, Michaelis J, Nicholson S, Pötschger U, Pritchard J, Ladisch S, Histiocyte Society (2001) A randomized trial of treatment for multisystem Langerhans cell histiocytosis. Pediatrics 138:728–734CrossRefGoogle Scholar
  4. 4.
    Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F (1997) Langerhans’-cell histiocytosis in adults. Med Pediatr Oncol 28:9–14PubMedCrossRefGoogle Scholar
  5. 5.
    Montella L, Insabato L, Palmieri G (2004) Imatinib mesylate for cerebral Langerhans’-cell histiocytosis. N Engl J Med 351:1034–1035PubMedCrossRefGoogle Scholar
  6. 6.
    Lau LM, Stuurman K, Weitzman S (2008) Skeletal Langerhans cell histiocytosis in children: permanent consequences and health-related quality of life in long-term survivors. Pediatr Blood Cancer 50(3):607–612PubMedCrossRefGoogle Scholar
  7. 7.
    García de Marcos JA, Ferrer AD, Granados FA, Masera JJR, Sánchez GB, Ortiz AIR, Calderón Bohórquez JM, Salas BV (2007) Langerhans cell histiocytosis in the maxillofacial area in adults. Report of three cases. Med Oral Patol Oral Cir Bucal 12:E145–E150PubMedGoogle Scholar
  8. 8.
    Arzoo K, Sadeghi S, Pullarkat V (2001) Pamidronate for bone pain from osteolytic lesions in Langerhans’-cell histiocytosis. N Engl J Med 345:225PubMedCrossRefGoogle Scholar
  9. 9.
    Farran RP, Zaretski E, Egeler RM (2001) Treatment of Langerhans cell histiocytosis with pamidronate. Pediatr Hematol Oncol 23:54–56CrossRefGoogle Scholar
  10. 10.
    Kamizono J, Okada Y, Shirahata A, Tanaka Y (2002) Bisphosphonate induces remission of refractory osteolysis in langerhans cell histiocytosis. J Bone Miner Res 17:1926–1928PubMedCrossRefGoogle Scholar
  11. 11.
    Coleman RE (2004) Bisphosphonates: clinical experience. Oncologist 9(suppl 4):14–27PubMedCrossRefGoogle Scholar
  12. 12.
    Green JR (2004) Bisphosphonates: preclinical review. Oncologist 9(suppl 4):3–13PubMedCrossRefGoogle Scholar
  13. 13.
    Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E (1999) Differential in situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood 94:4195–4201PubMedGoogle Scholar

Copyright information

© The Japanese Society for Bone and Mineral Research and Springer 2008

Authors and Affiliations

  1. 1.Medical Oncology UnitS. Giovanni di Dio HospitalNaplesItaly
  2. 2.Casa di Cura Villa Maria, Mirabella EclanoAvellinoItaly
  3. 3.Molecular and Clinical Endocrinology and Oncology DepartmentFederico II UniversityNaplesItaly

Personalised recommendations